TY - JOUR T1 - The Utility of Gallium-68 DOTATOC PET/CT in Lymphangioleiomyomatosis JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00397-2021 SP - 00397-2021 AU - Brian Gaffney AU - Evelyn Lynn AU - Jonathan D. Dodd AU - Michael P. Keane AU - David J. Murphy AU - Cormac McCarthy Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/07/22/23120541.00397-2021.abstract N2 - Lymphangioleiomyomatosis (LAM) is a progressive diffuse cystic lung disease. FEV1 is the current outcome measure, however this may underestimate disease burden; better activity biomarkers are needed. Previous reports suggested the presence of somatostatin or analogous receptors in LAM. We hypothesised that Ga68-DOTA PET/CT, utilising a radiolabelled somatostatin analogue could be a molecular imaging technique to demonstrate disease burden. There were no differences in tracer uptake in LAM patients compared to controls and no correlations between PET/CT values and pulmonary-function. This report indicates that somatostatin molecular imaging in LAM is not useful, however other functional imaging approaches may be of benefit.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. ER -